

OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934  
or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person * <u>Crouse Steven C.</u>  (Last) (First) (Middle) 614 MCKINLEY PLACE NE  (Street) MINNEAPOLIS MN 55413  (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 03/01/2026	3. Issuer Name and Ticker or Trading Symbol <u>BIO-TECHNE Corp [ TECH ]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) President - Diag & Spatial Bi	5. If Amendment, Date of Original Filed (Month/Day/Year)  6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Beneficially Owned**

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	5,894	D	

**Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date				
Restricted Stock Units	(2)	(2)	Common Stock	1,588	(1)	D
Restricted Stock Units	(3)	(3)	Common Stock	1,800	(1)	D
Restricted Stock Units	(4)	(4)	Common Stock	1,379	(1)	D
Restricted Stock Units	(5)	(5)	Common Stock	3,737	(1)	D
Restricted Stock Units	(6)	(6)	Common Stock	6,529	(1)	D
Stock Option (right to buy)	(7)	04/01/2028	Common Stock	3,856	97.13	D
Stock Option (right to buy)	(7)	08/06/2028	Common Stock	19,032	120.46	D
Stock Option (right to buy)	(8)	08/15/2029	Common Stock	24,560	94.52	D
Stock Option (right to buy)	(9)	08/15/2030	Common Stock	12,649	84.61	D
Stock Option (right to buy)	(10)	05/01/2031	Common Stock	7,327	73.46	D
Stock Option (right to buy)	(11)	08/15/2034	Common Stock	17,133	74.91	D
Stock Option (right to buy)	(12)	06/02/2035	Common Stock	5,434	48.61	D
Stock Option (right to buy)	(13)	08/15/2035	Common Stock	19,151	53.6	D

**Explanation of Responses:**

- Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
- 794 restricted stock units vest on 5/1/2026 and 5/1/2027.
- 600 restricted stock units vest on each of 6/2/2026, 6/2/2027 and 6/2/2028.
- 1,379 restricted stock units vest on 8/15/2026.
- 1,868 restricted stock units vest on 8/15/2026 and 1,869 restricted stock units vest on 8/15/2027.
- 2,176 restricted stock units vest on each of 8/15/2026 and 8/15/2028; and 2,177 restricted stock units vest on 8/15/2027.
- 100% vested.
- Options to purchase 6,140 shares vest on each of 8/15/2023, 8/15/2024, 8/15/2025 and 8/15/2026.
- Options to purchase 3,162 shares vest on each of 8/15/2024, 8/15/2026 and 8/15/2027; and options to purchase 3,163 shares vest on 8/15/2025.
- Options to purchase 1,832 shares vest on each of 5/1/2025, 5/1/2026 and 5/1/2028; and options to purchase 1,831 shares vest on 5/1/2027.
- Options to purchase 4,283 shares vest on each of 8/15/2025, 8/15/2027 and 8/15/2028; and options to purchase 4,284 shares vest on 8/15/2026.
- Options to purchase 1,359 shares vest on each of 6/2/2026 and 6/2/2028; and options to purchase 1,358 shares vest on each of 6/2/2027 and 6/2/2029.
- Options to purchase 4,788 shares vest on each of 8/15/2026, 8/15/2027 and 8/15/2029; and options to purchase 4,787 shares vest on 8/15/2028.

/s/ Andrew Nick as Attorney-in-  
Fact for Steven C. Crouse pursuant  
to Power of Attorney filed 03/04/2026  
herewith.

\*\* Signature of Reporting Person      Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**

POWER OF ATTORNEY

The undersigned hereby constitutes and appoints James Hippel, Anna Weispfenning, Andrew Nick, Sara Tucher or either of them acting alone, the undersigned's true and lawful attorneys-in-fact and agent with full power of substitution and resubstitution, for the undersigned and in the undersigned's name, place and stead, in any and all capacities, to sign any or all Forms 3, Forms 4 and Forms 5 relating to beneficial ownership of securities of Bio-Techne Corporation (the "Issuer"), to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission and to deliver a copy of the same to the Issuer, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as the undersigned might or could do in person, hereby ratifying and confirming all said attorneys-in-fact and agent, or his substitute or substitutes, may lawfully do or cause to be done by virtue thereof. The undersigned acknowledges that the foregoing attorney-in-fact, in serving in such capacity at the request of the undersigned, is not assuming any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934.

This Power of Attorney shall remain in effect until such time as the undersigned is no longer subject to the provisions of Section 16 of the Securities Exchange Act of 1934 with respect to securities of the Issuer.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 4th day of March, 2026.

/s/ Steven C. Crouse